MSD/Pfizer’s diabetes drug Steglatro hits goal in CV outcomes trial
The drug was shown to be as safe as placebo on a composite of CV death, nonfatal myocardial infarction or nonfatal stroke
Read More
Tag: Steglatro
NICE recommendation for Steglatro in type II diabetes
MSD’s SGLT-2 inhibitor Steglatro will be available for some patients with type II diabetes on the NHS in England and Wales.
Read More
Seven medicines leap closer to EU approval
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has put forward seven new medicines for approval in the region, including new treatment options for haemophilia A, diabetes, and a very rare genetic disorder.
Read More
US green light for Pfizer/Merck diabetes therapies
Pfizer and Merck’s diabetes drugs Steglatro and Steglujan have been approved for the US market.
Read More
- Laigo Bio completes final close of €17m seed financing round
- Axplora announces expansion as newest part of $60m API investment programme
- DNA Script signs SYNTAX distribution agreements with Gencell, BMS and Biostream
- Ondine’s Steriwave phase 3 trial reaches 93% enrolment milestone
- Arvinas reports strong phase 1 results for ARV-102 in Parkinson’s disease
